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a b s t r a c t
The anticancer drug Irinotecan (CPT11) is known to trigger the induction of ATP-Binding
Cassette (ABC) transporters, responsible for the efflux of the drug and its metabolites
outside of the cells. The drug-modulated overexpression of those transporters prevents
its accumulation in the intracellular medium, therefore decreasing its efficacy. A critical
clinical concern lies in the design of CPT11-based therapeutic strategies which eradicate
a maximum number of cancer cells despite their ability to become resistant. In order to
address this issue, we supplemented an existing mathematical model of CPT11 molecular
pharmacokinetics–pharmacodynamics (PK–PD) with a new model of CPT11-induced
overexpression of ABC transporters. We then theoretically optimized exposure to CPT11
given as a single agent or combined either with ABC transporter inhibitors, or with
inhibitors of nuclear factorswhose activation is responsible for transporter overexpression.
We firstly considered a cancer cell population endowed with the ability of inducing their
transporters. For any drug combination, we concluded that the highest concentration
of CPT11 should be administered in order to kill a maximum number of cancer cells,
despite the triggering of resistance. We then considered a population of healthy cells
which were assumed to be identical to cancer cells except that they were not able to
become resistant. Optimal schemes were defined as the ones which maximized DNA
damage in cancer cells under the constraint of DNA damage in healthy cells not exceeding a
tolerability threshold. The optimal therapeutic strategy consisted in combining CPT11with
ABC transporter inhibitors as it achieved a complete reversal of resistance by means of the
lowest concentrations of CPT11.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Multidrug resistance (MDR) is characterized by the ability of cancer cells to become simultaneously resistant to many
anticancer drugs. A possible cellular mechanism of MDR is the drug-modulated induction of ATP-Binding Cassette (ABC)
transporters which actively pump molecules outside of the cells [1]. The enhancement of ABC transporter expression in
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tumor tissues prevents anticancer drugs from accumulating in the intracellular medium and therefore decreases their
efficacy. Irinotecan (CPT11) is a cytotoxic drug approved for the treatment of colorectal cancer [2]. CPT11 is a substrate for
several ABC transporters and is known to trigger their induction in cancer cell lines [3–5]. We propose here to theoretically
optimize CPT11-based therapeutic strategies in the case of MDR.
To address this concern, we designed a mathematical model for CPT11-driven transporter induction by extending an
existing model of CPT11 molecular pharmacokinetics–pharmacodynamics (PK–PD) [6]. We then theoretically investigated
optimal therapeutic strategies which circumvent resistance in cancer cells. We firstly searched for exposure schemes which
maximizedDNAdamagewithin a population of cancer cells endowedwith the ability of inducing their transporters. Thenwe
considered a second population defined as healthy cells which were identical to the cancer ones except that they were not
endowed with the considered resistant mechanism. Optimal exposure schemes were defined as the ones that maximized
DNA damage in cancer cells under the constraint of DNA damage in healthy cells not exceeding a tolerability threshold. We
investigated three drug combinations: CPT11 given as a single agent, combinedwith ABC transporter inhibitors, or combined
with inhibitors of nuclear factors whose activation is responsible for ABC transporter induction.
2. The existing mathematical model of CPT11 molecular PK–PD
A mathematical model of CPT11 molecular PK–PD was previously built and fitted to in vitro experimental data [6]. It
describes molecular events occurring within a cell population during CPT11 exposure. Briefly, CPT11 in the intracellular
medium (CPTin) is converted into its active metabolite SN38 (SNin) under the catalytic activity of carboxylesterases (CES).
SN38 is deactivated into SN38G through UDP-glucuronosyltransferase enzymes (UGT ) [2]. CPT11, SN38 and SN38G are
assumed to enter passively into the cytoplasm but to be actively expelled outside of the cells by several transporters of the
ABC superfamily. The variable ABC_CPT represents transporters responsible for CPT11 efflux and stands for the cumulative
activity of ABCB1, ABCC1 and ABCC2. Transporters of SN38 and SN38G are denoted by the variable ABC_SN which represents
the activity of ABCC1, ABCC2 and ABCG2 [6].
d[CPTin]
dt
= kupCPT [CPTout ] − VeffCPT [ABC_CPT ][CPTin]KeffCPT + [CPTin] −
Vces[CES][CPTin]
Kces + [CPTin] (1)
d[SNin]
dt
= kupSN [SNout ] − VeffSN [ABC_SN][SNin]KeffSN + [SNin] +
Vces[CES][CPTin]
Kces + [CPTin]
− Vugt [UGT ][SNin]
Kugt + [SNin] − kf 2[DNATOP1][SN38in] + kr2[Compl]. (2)
CPT11 is an inhibitor of topoisomerase 1 (TOP1), an enzyme which relaxes supercoiled DNA by creating transient single-
stranded breaks [7]. The active metabolite SN38 stabilizes DNA/TOP1 complexes into reversible SN38/TOP1/DNA ones
(Compl) which still spontaneously dissociate but at a much slower rate. Collisions between those ternary complexes and
replication or transcriptionmechanisms create irreversible DNA damage (Icompl) which trigger DNA repair, cell cycle arrest
and lead possibly to apoptosis [7]. Icompl is the output variable of the model as it has been experimentally correlated with
CPT11 cytotoxicity [6].
d[Compl]
dt
= kf 2[DNATOP1][SNin] − kr2[Compl] − kIrr [Compl] (3)
d[Icompl]
dt
= kIrr [Compl]. (4)
3. Adding CPT11-modulated ABC transporter induction
CPT11 exposuremay enhance the expression of ABCB1 andABCG2both in cancer cell lines and in tumor tissues in patients
[3–5]. Therefore we supplemented the existing mathematical model of CPT11 PK–PD with a representation of the drug-
driven transporter induction.
A possible molecular mechanism leading to this induction consists in the activation by CPT11-induced DNA damage of
nuclear factors which then promote the expression of ABC transporters (Fig. 1). Indeed, in cancer cell lines, DNA double-
stranded breaks resulting from CPT11 exposure activate the nuclear factor NF-κB [8–10] which enhances ABCB1 expression
[11,12]. In the same way, chemical stress may activate the nuclear factor NRF-2 which is known to promote the expression
of ABCG2, ABCC1 and ABCC2 [13–16].
We thus propose the following model for mRNA and protein amounts of ABC transporters responsible for CPT11 and
SN38 efflux:
d[ABC_XRNA]
dt
= kfRNA + kind [Icompl]
n
thnind + [Icompl]n
− kdRNA[ABC_XRNA] (5)
d[ABC_XProt ]
dt
= kfABC [ABC_XRNA] − kdABC [ABC_XProt ] (6)
A. Ballesta et al. / Applied Mathematics Letters 24 (2011) 1251–1256 1253
Fig. 1. CPT11-driven transporter induction CPT11 in the extracellular medium (CPTout ) enters passively in the cytoplasm (CPTin). It is then actively
expelled outside of the cells by efflux pumps called ABC transporters. CPTin creates DNA damage responsible for the activation of nuclear factors which
promote ABC transporter expression. The enhanced active efflux results in a decreased intracellular drug concentration and therefore confers resistance
to the cells.
where ABC_X stands either for ABC_CPT or for ABC_SN . In the absence of CPT11, ABC transportermRNA expression ABC_XRNA
is the result of transcription (kfRNA) and degradation (kdABC ). ABC transporter proteins ABC_XProt arise from the translation of
ABC_XRNA (kfABC ) and are degraded by the cell (kdABC ). mRNAmolecules were assumed not to be consumed by the translation
mechanism as one mRNA molecule may produce several proteins.
Nuclear factor activation by CPT11 is phenomenologically modeled in Eq. (5) by an S-shaped function which shows a
steep increase when DNA damage (Icompl) exceeds the induction threshold thind. Indeed experimental results show that
CPT11 induces a rapid and transient activation of the nuclear factor NF-κB which is dose-dependent and rapidly saturates
when the dose of CPT11 is increased [9,10]. This modeling choice results in a persistent overexpression of transportermRNA
and protein amounts which lasts after the drug exposure. Indeed the reversal of transporter induction was observed only
after two months in cultured cell lines [4]. It is neglected here since our concern is to design short-term optimal exposure
schemes.
For the sake of simplicity, we assumed that ABC_XRNA and ABC_XProt are equal to 1 µM at steady state in the absence of
drug and therefore set kfRNA = 1 µM, kdRNA = 1 h−1 and kfABC = kdABC . We assumed that this is the first time that cells are
exposed to CPT11. Therefore, at the initial instant, transporter mRNA and protein amounts are equal to 1. All other variables
are equal to 0 except CPT11 extracellular concentration which is set to the chosen exposure concentration.
Other parameter values were estimated by fitting experimental data from the literature in which a 6-fold increase in
ABCB1 mRNA level and a 2-fold increase in its protein amount were observed after 96 h of exposure to SN38 [3]. We
assumed that these kinetics occurred for an exposure to 80 µM of CPT11 and obtained: n = 20, kfABC = kdABC = 0.1 h−1,
kind = 5 µM h−1 and thind = 0.13 µM.
4. Optimal therapeutic strategies in the case of MDR
4.1. Considered drug combinations
The aim of this part is to optimize CPT11-based therapeutics in the case of MDR. Clinical strategies aiming at reversing
MDR mainly consist in inhibiting ABC transporters by pharmacological agents [1]. Another possibility inferred from
mathematical modeling consists in inhibiting nuclear factors. Several inhibitors of NF-κB are currently under clinical studies
[17]. Their administration in combination with CPT11 do enhance cell sensitivity to the drug. However, NF-κB displays a
well-studied anti-apoptotic activity, which inhibitionmay be responsible for this increase in cell death [18,19].We therefore
considered three drug combinations: CPT11 given as a single agent, combined with ABC transporter inhibitors or combined
with nuclear factor inhibitors.
CPT11 administration consisted in exposing cells to an extracellular medium containing the drug at an initial
concentration ranging from 0 to 3000 µM. This interval of concentrations was chosen as it resulted in SN38 extracellular
concentrations between 0 and 0.15 µM in the absence of transporter induction, which are physiological values for SN38
blood concentration in patients [20]. Exposure duration was searched between 1 and 168 h. Transporter or nuclear factor
inhibitor administration was assumed to start before CPT11 exposure so that the system was at steady state when CPT11
was added to the culture medium. Nuclear factor inhibitors were modeled by setting kind to 0 for ABC_CPT and ABC_SN,
which corresponds to a complete inhibition. ABC transporter inhibitors I_ABC weremodeled as competitive inhibitorswhich
irreversibly trap transporters into complexes:
[ABC_XProt ]
dt
= kfABCABC_XRNA − kdABC [ABC_XProt ] − kinhib[I_ABC][ABCProt ] (7)
[I_ABC]
dt
= −kinhib[I_ABC][ABC_XProt ]. (8)
Inhibitor concentrations were assumed to be high enough to completely inhibit transporters in the absence of drug-driven
induction. Therefore, ABC_CPT and ABC_SN were set to 0 at the initial instant. Inhibitor concentrations were set to 200 µM
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Fig. 2. Maximizing DNA damage in cancer cells without tolerability constraint. Time evolution of CPT11 and SN38 in intra and extracellular
compartments, of ABC_CPT transporter protein amount and of the drug-induced irreversible complexes Icompl, during optimal exposure to CPT11
given as a single agent (black), combined with nuclear factor inhibitors (red), or with ABC transporter inhibitors (blue). For any drug combination, the
optimal exposure scheme consisted in administering the highest concentration of CPT11 (3000 µM) over the longest duration (168 h). When CPT11
was administered as a single agent, cancer cells increased ABC transporter expression so that the intracellular concentrations of CPT11 and SN38 were
decreased, and thus created less DNA damage. The co-administration of nuclear factor or ABC transporter inhibitors prevented transporter overexpression
and increased CPT11-induced DNA damage. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
at initial instant and kinhib was set to 1 so that the inhibition of transporter induction was rapid and complete. For each drug
combination, the optimization procedure consisted in searching for the optimal concentration of CPT11 and the optimal
exposure duration.
4.2. Maximizing DNA damage within cancer cells
First, we considered a population of cancer cells endowed with the mechanism of drug-driven transporter induction.
We searched for exposure schemes which maximized DNA damage in these cancer cells without any tolerability constraint.
The optimization procedure consisted in minimizing the opposite of the variable Icompl using the evolutionary algorithm
CMAES [21].
For CPT11 given as a single agent, the optimal exposure scheme consisted in administering the highest concentration
of 3000 µM over the longest duration equal to 168 h, despite the triggering of resistance (Fig. 2). This result thus suggests
that cancer cells should be exposed to the highest tolerable dose of CPT11 so that the largest amount of DNA damage is
created before they overexpress their transporters. The same optimal exposure scheme was found when CPT11 was co-
administered with nuclear factor or transporter inhibitors, as no tolerability constraint was considered in this case. It can
be noted that in the case of CPT11 given as a single agent, SN38 extracellular concentration was largely higher than when
the drug was combined with inhibitors because SN38 enhanced efflux prevented its deactivation into SN38G which occurs
in the intracellular medium.
4.3. Maximizing DNA damage within cancer cells under a constraint of tolerability
Wethen considered a population of healthy cellswhichwere defined as identical to the previouslymentioned cancer cells
except that they were not endowed with the ability of enhancing ABC transporter expression in response to drug exposure.
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Fig. 3. Maximizing DNA damage in cancer cells with tolerability constraint Comparison of three therapeutic strategies: exposure to CPT11 as a single
agent (black, diamond), combined with nuclear factor inhibitors (red, circle), or combined with ABC transporter inhibitors (blue, circle). A. DNA damage in
cancer cells with respect to the maximal allowed DNA damage in healthy cells: combining CPT11 with inhibitors of nuclear factors or of ABC transporters
completely reversed the resistance of cancer cells. B. Optimal concentrations with respect to maximal allowed DNA damage in healthy cells: optimal
concentrations in the case of CPT11 combined with nuclear factor inhibitors were approximately half the ones found when CPT11 was given as a single
agent. Combining CPT11 with ABC transporter inhibitors allowed a larger decrease in the optimal concentration to be administered. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
Optimal exposure schemeswere defined as the one thatmaximized DNA damage in cancer cells under the constraint of DNA
damage in healthy cells not exceeding a tolerability threshold [6,22].Wedetermined optimal exposure schemes for a toxicity
threshold ranging from 0.1 to 0.5 µM of DNA-bound SN38. The optimization procedure consisted in the minimization by
the CMAES algorithm of a cost function which was the sum of two terms. The first term consisted in the opposite of DNA
damage Icompl in cancer cells which typically ranged from 0 to 0.5µMof DNA-bound SN38. The second term accounted for
the toxicity constraint. It was equal to 0 when Icompl in healthy cells was under the tolerability threshold and became equal
to 1000 otherwise. Optimization procedures gave the following results for each considered drug combination.
For any toxicity threshold, optimal exposure schemeswhen CPT11was given as a single agent consisted in administering
a concentration of 370–2700 µM over a duration ranging from 36–152 h, linearly increasing with the allowed toxicity
(Fig. 3). When the toxicity threshold was lower than the resistance threshold (0.13 µM of DNA-bound SN38), DNA damage
in healthy and cancer cells were the same since resistance was not triggered. On the contrary, when the induction threshold
was exceeded, the optimal exposure schemes resulted in 12% more DNA damage in healthy cells than in cancer cells which
triggered their resistance mechanism.
The combination of CPT11 with nuclear factor inhibitors allowed a decrease in optimal concentrations of CPT11 which
were equal to approximately half the ones found when CPT11 was given as a single agent, optimal exposure durations
remaining the same (Fig. 3). Moreover, the administration of nuclear factor inhibitors completely annihilated the advantage
of resistant cells so that DNA damage in healthy and cancer cells were equal.
The use of ABC transporter inhibitors combined with CPT11 further decreased optimal concentrations of CPT11 to be
administered which ranged between 150 and 290 µM (Fig. 3). Optimal durations were slightly decreased compared to the
other drug combinations and linearly increased with the allowed toxicity from 32 to 148 h. This strategy also allowed a
complete circumvent of resistance as DNA damage in healthy and cancer cells were equal. We therefore concluded that this
strategy was the optimal one as it involved the lowest concentrations of CPT11 to completely reverse resistance.
5. Discussion
To the best of our knowledge, two other published works modeled ABC transporter induction. A mathematical model of
doxorubicin PK–PD includes transporter overexpression which is assumed to be directly proportional to the intracellular
drug concentration [23]. This modeling assumption does not render an account of the experimentally observed threshold
on drug concentrations above which resistance is triggered. Moreover, this model allows the quantity of ABC transporters
to grow to infinity in the case of large drug concentrations. Our modeling choice prevents ABC transporter amount to grow
to infinity as the induction term rapidly reaches its maximal value kind when DNA damage Icompl increases.
Another work models the molecular PK–PD of 5-fluorouracil and includes the drug-induced transporter overexpression
[20]. In this model, the nuclear factor remains activated as long as the drug intracellular concentration exceeds an induction
threshold. However NF-κB kinetics in the presence of CPT11 consists in a transient activation of few hours which vanishes
before the drug removal [9]. Furthermore, this modeling choice implies that killing a maximum number of cancer cells is
achieved by an exposure to a dose below the induction threshold during a long period in order not to trigger the resistant
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mechanism. On the contrary, our model concludes that the resistant mechanism is going to be triggered anyhow and that
the highest tolerable dose should be given during the first cell exposure in order to kill a maximum number of cancer cells
before they overexpress their transporters and become resistant.
This study concludes that combining ABC transporter inhibitors with CPT11 is the optimal therapeutic strategy as it
involved the lowest concentrations of CPT11 to completely reverse MDR. However, we did not take into account the
possible toxicity induced by the inhibitors themselves. Indeed several ABC transporter inhibitors display bone-marrow and
neurological toxicity [1].
6. Conclusion
This article presents an extended model of CPT11 molecular PK–PD which includes the drug-induced transporter
overexpression. The model predicted that, in order to kill a maximum number of resistant cells, the highest tolerable
concentration of CPT11 should be administered during the first exposure, in order to create the largest amount of DNA
damage when cells have not overexpressed their transporters yet. Now considering a tolerability constraint, we concluded
that the combination of CPT11with ABC transporter inhibitorswas the optimal therapeutic strategy as it allowed a complete
reversal of resistance by means of the lowest concentrations of CPT11.
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